Esperion Therapeutics (ESPR) Gross Margin (2019 - 2026)

Esperion Therapeutics has reported Gross Margin for 8 years, with the latest figure at 56.84% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 536.0% year-over-year to 56.84%; the trailing twelve-month figure through Mar 2026 stood at 42.76% (down 2254.0% YoY), and the FY2024 full-year result was 79.36%, up 1655.0% from the prior year.
• Gross Margin for Q1 2026 stood at 56.84%, up from 52.71% in the prior quarter.
• The five-year high for Gross Margin was 92.69% in Q1 2024, with the low at 51.3% in Q2 2022.
• Historically, Gross Margin has averaged 64.71% across 5 years, with a median of 63.7% in 2023.
• Annual changes were most pronounced in 2022 — Gross Margin sank 4428 bps — and 2024, when it surged 4058 bps.
• Esperion Therapeutics' Gross Margin stood at 77.89% in 2022, then fell by 17 bps to 64.49% in 2023, then fell by 2 bps to 62.91% in 2024, then slipped by 16 bps to 52.71% in 2025, then climbed by 8 bps to 56.84% in 2026.
• The last three Gross Margin figures came in at 56.84% (Q1 2026), 52.71% (Q3 2025), and 65.35% (Q2 2025), per Business Quant data.